Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly (NYSE: LLY) stock price has quietly become one of the best-performing stocks in the past few years. The shares are trading at their all-time high of $605.28, higher than the 2009 low of $14.

Eli Lilly (LLY) stock price is flying: buy the Nvidia of pharma

Conagra Brands

Novo Nordisk

PepsiCo

J. M. Smucker

Walmart

But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?

Will Higher Ozempic Use Mean Slimmed-Down Food Sales?

Eli Lilly said on Thursday its experimental drug met the main goals of a late-stage study to test it as a treatment for moderately to severely active Crohn's disease, a type of inflammatory bowel disease.

Lilly's bowel disease drug succeeds in late-stage study

Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks The study achieved the coprimary endpoints and all major secondary endpoints versus placebo This successful Phase 3 trial will be the basis of global regulatory submissions for Crohn's disease INDIANAPOLIS , Oct. 12, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn's disease. The double-blind, treat-through trial included mirikizumab, placebo and active control (ustekinumab) arms.

Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial

Eli Lilly is expected to receive FDA approval for tirzepatide, an obesity medication, and has two other medications in phase 3 clinical studies. The GLP-1 therapy market is projected to reach $150 billion in the US by 2030, with a potential 30% of the obese population using it. Recent developments, including positive trial results and increased employer coverage for obesity medications, strengthen the outlook for Eli Lilly's growth.

Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated

Is Eli Lilly stock a buy after rival Novo Nordisk said its diabetes drug showed promise in kidney disease treatment? Is LLY stock a buy?

Eli Lilly Sparks As Rival Novo Says Diabetes Drug Could Treat Kidney Disease — But Is Lilly Stock A Buy?

Baxter

Fresenius Medical Care

Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo Nordisk (NYSE:NVO) revealed that its Ozempic – a weekly jab which also doubles as a weight-loss aid – had proven successful in treating the new patient group mentioned above.

Novo Nordisk data knocks $5bn from the value of three leading dialysis companies

DaVita

Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.

Ozempic Is Moving a Bunch of Stocks Wednesday Morning

Eli Lilly and Co (NYSE:LLY) shares were trading 2.6% higher pre-market after a positive read-across from a key trial read-out from its main rival in the weight-loss market. Denmark's Novo Nordisk (NYSE:NVO) stopped a trial early after it emerged its Ozempic jab had been a resounding success in treating kidney failure in diabetes.

Eli Lilly gets $14bn boost from Ozempic data - here's what's happened

Arista Networks

Booking Hlds

Cadence Design Systems

Alphabet

Palo Alto Networks

Synopsys

SPDR S&P 500 ETF Trust

West Pharmaceutical Services

Risk and reward are supposed to be attached at the hip for S&P 500 stocks. But a small group of stocks are delivering all gain and no pain.

9 'Unstoppable' Stocks Deliver Big Gains And No Pain To Investors

Bristol-Myers

Mirati Therapeutics

Pfizer

Point Biopharma Global

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

AUSTIN, Texas--(BUSINESS WIRE)--Lilly Endowment Inc., a philanthropic foundation committed to supporting causes of community development, education, and religion, granted Wesleyan Impact Partners $1.25 million to fund the Phygital Preaching Fellows initiative as part of Lilly Endowment's Compelling Preaching Initiative. The initiative aims to foster and support preaching that inspires, encourages, and guides people to come to know and love God and to live out their Christian faith more fully. T.

Wesleyan Impact Partners Receives $1.25 Million Grant from Lilly Endowment

According to the results of a recent survey, inclusion of weight-loss drugs is set to ramp up dramatically. More than a few businesses plan to include such coverage in their healthcare insurance policies in 2024.

Why Eli Lilly Stock Crawled Higher Today

The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey. The survey of 502 employers by Accolade , a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

McKesson

Novartis

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-average support.

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

CAMBRIDGE, Mass.--(BUSINESS WIRE)--This announcement marks Foundation Medicine's fifth pan-tumor approval in the U.S. for FoundationOne CDx.

U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly's Retevmo® (selpercatinib) for Certain Patients with Solid Tumors

Ginkgo Bioworks Holdings

Vertex Pharmaceuticals

While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotech stocks as much.

3 Biotech Stocks Ready to Break Out in 2024

Shares of Eli Lilly and Co (NYSE:LLY) rose Friday after analysts at Bank of America reaffirmed its confidence in the company. The firm reiterated its Buy rating and upped its price target to $700 from $600.

Eli Lilly pipeline of obesity treatments is positioned to pay off beyond just Mounjaro, analysts say

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of POINT Biopharma Global, Inc. (NasdaqCM: PNT) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of POINT will receive $12.50 in cash for each share of POINT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT

Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

INDIANAPOLIS , Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.  Presentation Highlights Verzenio (abemaciclib) In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Lilly Announces Details of Presentations at ESMO Congress 2023

Eli Lilly set out to launch four new products this year, but it is unlikely to do so. The company's regulatory roadblocks aren't deal-breakers for its medicines.

Should You Sell This Stock After Another Regulatory Headwind?

Intuitive Surgical

What Are The Best Stocks To Invest In? 2 Healthcare Stocks To Know

There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.

Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)

INDIANAPOLIS , Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston. These programs are among the next slate of new oncology agents planned to enter clinical trials for Loxo@Lilly in 2024.

News for Eli Lilly Stock (LLY)